2023-2029 Global Immune-mediated Necrotizing Myopathy Treatment Industry Research & Trends Analysis Report
According to YH Research, the global market for Immune-mediated Necrotizing Myopathy Treatment should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
China Immune-mediated Necrotizing Myopathy Treatment market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
The United States Immune-mediated Necrotizing Myopathy Treatment market should grow from US$ million in 2022 to US$ million by 2029, with a CAGR of % for the period of 2023-2029.
In terms of type, Steroids segment holds a share about % in 2022 and will reach % in 2029; while in terms of application, Hospital has a share approximately % in 2022 and will grow at a CAGR % during 2023 and 2029.
The global key manufacturers of Immune-mediated Necrotizing Myopathy Treatment include GlaxoSmithKline plc, Dr. Reddy's Laboratories, Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.), Hetero Drugs Limited, AbbVie Inc., Teva Pharmaceutical Industries and Novartis AG, etc. In 2022, the global top five players hold a share approximately % in terms of revenue.
This report aims to provide a comprehensive study of the global market for Immune-mediated Necrotizing Myopathy Treatment. Report Highlights:
(1) Global Immune-mediated Necrotizing Myopathy Treatment market size (value), history data from 2018-2022 and forecast data from 2023 to 2029.
(2) Global Immune-mediated Necrotizing Myopathy Treatment market competitive situation, revenue and market share, from 2018 to 2022.
(3) China Immune-mediated Necrotizing Myopathy Treatment market competitive situation, revenue and market share, from 2018 to 2022.
(4) Global Immune-mediated Necrotizing Myopathy Treatment segment by region (or country), key regions cover the United States, Europe, Japan, South Korea, Southeast Asia and India, etc.
(5) Global Immune-mediated Necrotizing Myopathy Treatment segment by type and by application and regional segment by type and by application.
(6) Immune-mediated Necrotizing Myopathy Treatment industry supply chain, upstream, midstream and downstream analysis.
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Market segment by type, covers
Steroids
Immunosuppressant
Others
Market segment by application, can be divided into
Hospital
Clinic
Others
Market segment by players, this report covers
GlaxoSmithKline plc
Dr. Reddy's Laboratories
Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
Hetero Drugs Limited
AbbVie Inc.
Teva Pharmaceutical Industries
Novartis AG
1 Market Overview
1.1 Product Overview and Scope of Immune-mediated Necrotizing Myopathy Treatment
1.2 Global Immune-mediated Necrotizing Myopathy Treatment Market Size and Forecast
1.3 China Immune-mediated Necrotizing Myopathy Treatment Market Size and Forecast
1.4 China Market Percentage in Global
1.4.1 By Revenue, China Immune-mediated Necrotizing Myopathy Treatment Share in Global Market, 2018-2029
1.4.2 Immune-mediated Necrotizing Myopathy Treatment Market Size: China VS Global, 2018-2029
1.5 Immune-mediated Necrotizing Myopathy Treatment Market Dynamics
1.5.1 Immune-mediated Necrotizing Myopathy Treatment Market Drivers
1.5.2 Immune-mediated Necrotizing Myopathy Treatment Market Restraints
1.5.3 Immune-mediated Necrotizing Myopathy Treatment Industry Trends
1.5.4 Immune-mediated Necrotizing Myopathy Treatment Industry Policy
2 Global Competitive Situation by Company
2.1 Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Company (2018-2023)
2.2 Global Immune-mediated Necrotizing Myopathy Treatment Participants, Market Position (Tier 1, Tier 2 and Tier 3)
2.3 Global Immune-mediated Necrotizing Myopathy Treatment Concentration Ratio
2.4 Global Immune-mediated Necrotizing Myopathy Treatment Mergers & Acquisitions, Expansion Plans
2.5 Global Immune-mediated Necrotizing Myopathy Treatment Manufacturers Product Type
3 China Competitive Situation by Company
3.1 China Immune-mediated Necrotizing Myopathy Treatment Revenue by Company (2018-2023)
3.2 China Immune-mediated Necrotizing Myopathy Treatment Immune-mediated Necrotizing Myopathy Treatment Participants, Market Position (Tier 1, Tier 2 and Tier 3)
3.3 China Immune-mediated Necrotizing Myopathy Treatment, Revenue Percentage of Local Players VS Foreign Manufacturers (2018-2023)
4 Industry Chain Analysis
4.1 Immune-mediated Necrotizing Myopathy Treatment Industry Chain
4.2 Immune-mediated Necrotizing Myopathy Treatment Upstream Analysis
4.3 Immune-mediated Necrotizing Myopathy Treatment Midstream Analysis
4.4 Immune-mediated Necrotizing Myopathy Treatment Downstream Analysis
5 Sights by Type
5.1 Immune-mediated Necrotizing Myopathy Treatment Classification
5.1.1 Steroids
5.1.2 Immunosuppressant
5.1.3 Others
5.2 By Type, Global Immune-mediated Necrotizing Myopathy Treatment Market Size & CAGR, 2018 VS 2022 VS 2029
5.3 By Type, Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029
6 Sights by Application
6.1 Immune-mediated Necrotizing Myopathy Treatment Segment by Application
6.1.1 Hospital
6.1.2 Clinic
6.1.3 Others
6.2 By Application, Global Immune-mediated Necrotizing Myopathy Treatment Market Size & CAGR, 2018 VS 2022 VS 2029
6.3 By Application, Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029
7 Sales Sights by Region
7.1 By Region, Global Immune-mediated Necrotizing Myopathy Treatment Market Size, 2018 VS 2022 VS 2029
7.2 By Region, Global Immune-mediated Necrotizing Myopathy Treatment Market Size, 2018-2029
7.3 North America
7.3.1 North America Immune-mediated Necrotizing Myopathy Treatment Market Size & Forecasts, 2018-2029
7.3.2 By Country, North America Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share
7.4 Europe
7.4.1 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size & Forecasts, 2018-2029
7.4.2 By Country, Europe Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share
7.5 Asia Pacific
7.5.1 Asia Pacific Immune-mediated Necrotizing Myopathy Treatment Market Size & Forecasts, 2018-2029
7.5.2 By Country/Region, Asia Pacific Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share
7.6 South America
7.6.1 South America Immune-mediated Necrotizing Myopathy Treatment Market Size & Forecasts, 2018-2029
7.6.2 By Country, South America Immune-mediated Necrotizing Myopathy Treatment Market Size Market Share
7.7 Middle East & Africa
8 Sights by Country Level
8.1 By Country, Global Immune-mediated Necrotizing Myopathy Treatment Market Size & CAGR，2018 VS 2022 VS 2029
8.2 By Country, Global Immune-mediated Necrotizing Myopathy Treatment Market Size, 2018-2029
8.3 U.S.
8.3.1 U.S. Immune-mediated Necrotizing Myopathy Treatment Market Size, 2018-2029
8.3.2 By Company, U.S. Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2023
8.3.3 By Type, U.S. Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.3.4 By Application, U.S. Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.4 Europe
8.4.1 Europe Immune-mediated Necrotizing Myopathy Treatment Market Size, 2018-2029
8.4.2 By Company, Europe Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2023
8.4.3 By Type, Europe Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.4.4 By Application, Europe Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.5 China
8.5.1 China Immune-mediated Necrotizing Myopathy Treatment Market Size, 2018-2029
8.5.2 By Company, China Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2023
8.5.3 By Type, China Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.5.4 By Application, China Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.6 Japan
8.6.1 Japan Immune-mediated Necrotizing Myopathy Treatment Market Size, 2018-2029
8.6.2 By Company, Japan Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2023
8.6.3 By Type, Japan Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.6.4 By Application, Japan Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.7 South Korea
8.7.1 South Korea Immune-mediated Necrotizing Myopathy Treatment Market Size, 2018-2029
8.7.2 By Company, South Korea Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2023
8.7.3 By Type, South Korea Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.7.4 By Application, South Korea Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.8 Southeast Asia
8.8.1 Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Market Size, 2018-2029
8.8.2 By Company, Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2023
8.8.3 By Type, Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.8.4 By Application, Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.9 India
8.9.1 India Immune-mediated Necrotizing Myopathy Treatment Market Size, 2018-2029
8.9.2 By Company, India Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2023
8.9.3 By Type, India Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.9.4 By Application, India Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.10 Middle East & Asia
8.10.1 Middle East & Asia Immune-mediated Necrotizing Myopathy Treatment Market Size, 2018-2029
8.10.2 By Company, Middle East & Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2023
8.10.3 By Type, Middle East & Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
8.10.4 By Application, Middle East & Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
9 Global Manufacturers Profile
9.1 GlaxoSmithKline plc
9.1.1 GlaxoSmithKline plc Company Information, Head Office, Market Area and Industry Position
9.1.2 GlaxoSmithKline plc Company Profile and Main Business
9.1.3 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
9.1.4 GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
9.1.5 GlaxoSmithKline plc Recent Developments
9.2 Dr. Reddy's Laboratories
9.2.1 Dr. Reddy's Laboratories Company Information, Head Office, Market Area and Industry Position
9.2.2 Dr. Reddy's Laboratories Company Profile and Main Business
9.2.3 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
9.2.4 Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
9.2.5 Dr. Reddy's Laboratories Recent Developments
9.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.)
9.3.1 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Information, Head Office, Market Area and Industry Position
9.3.2 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Profile and Main Business
9.3.3 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
9.3.4 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
9.3.5 Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Developments
9.4 Hetero Drugs Limited
9.4.1 Hetero Drugs Limited Company Information, Head Office, Market Area and Industry Position
9.4.2 Hetero Drugs Limited Company Profile and Main Business
9.4.3 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
9.4.4 Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
9.4.5 Hetero Drugs Limited Recent Developments
9.5 AbbVie Inc.
9.5.1 AbbVie Inc. Company Information, Head Office, Market Area and Industry Position
9.5.2 AbbVie Inc. Company Profile and Main Business
9.5.3 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
9.5.4 AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
9.5.5 AbbVie Inc. Recent Developments
9.6 Teva Pharmaceutical Industries
9.6.1 Teva Pharmaceutical Industries Company Information, Head Office, Market Area and Industry Position
9.6.2 Teva Pharmaceutical Industries Company Profile and Main Business
9.6.3 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
9.6.4 Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
9.6.5 Teva Pharmaceutical Industries Recent Developments
9.7 Novartis AG
9.7.1 Novartis AG Company Information, Head Office, Market Area and Industry Position
9.7.2 Novartis AG Company Profile and Main Business
9.7.3 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
9.7.4 Novartis AG Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
9.7.5 Novartis AG Recent Developments
10 Conclusion
11 Appendix
11.1 Research Methodology
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Market Estimation Model
11.4 Disclaimer
Tables and Figures
Table 1. Immune-mediated Necrotizing Myopathy Treatment Market Size & CAGR: China VS Global, (US$ Million), 2018-2029
Table 2. Immune-mediated Necrotizing Myopathy Treatment Market Restraints
Table 3. Immune-mediated Necrotizing Myopathy Treatment Market Trends
Table 4. Immune-mediated Necrotizing Myopathy Treatment Industry Policy
Table 5. Global Immune-mediated Necrotizing Myopathy Treatment Revenue by Company (2018-2023) & (US$ million)
Table 6. Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Company (2018-2023)
Table 7. Global Immune-mediated Necrotizing Myopathy Treatment Manufacturers Market Concentration Ratio (CR3 and HHI)
Table 8. Global Immune-mediated Necrotizing Myopathy Treatment Mergers & Acquisitions, Expansion Plans
Table 9. Global Immune-mediated Necrotizing Myopathy Treatment Manufacturers Product Type
Table 10. China Immune-mediated Necrotizing Myopathy Treatment Revenue by Company (2018-2023) & (US$ million)
Table 11. China Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share by Company (2018-2023)
Table 12. Global Key Players of Immune-mediated Necrotizing Myopathy Treatment Upstream (Raw Materials)
Table 13. Global Immune-mediated Necrotizing Myopathy Treatment Typical Customers
Table 14. Immune-mediated Necrotizing Myopathy Treatment Typical Distributors
Table 15. By Type, Global Immune-mediated Necrotizing Myopathy Treatment Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 16. By Application, Global Immune-mediated Necrotizing Myopathy Treatment Revenue & CAGR, 2018 VS 2022 VS 2029, US$ Million
Table 17. By Region, Global Immune-mediated Necrotizing Myopathy Treatment Market Size, 2018 VS 2022 VS 2029, US$ Million
Table 18. By Region, Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029, US$ Million
Table 19. By Country, Global Immune-mediated Necrotizing Myopathy Treatment Revenue & CAGR，2018 VS 2022 VS 2029, US$ Million
Table 20. By Country, Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029, US$ Million
Table 21. By Country, Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2029
Table 22. GlaxoSmithKline plc Company Information, Head Office, Market Area and Industry Position
Table 23. GlaxoSmithKline plc Company Profile and Main Business
Table 24. GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
Table 25. GlaxoSmithKline plc Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
Table 26. GlaxoSmithKline plc Recent Developments
Table 27. Dr. Reddy's Laboratories Company Information, Head Office, Market Area and Industry Position
Table 28. Dr. Reddy's Laboratories Company Profile and Main Business
Table 29. Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
Table 30. Dr. Reddy's Laboratories Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
Table 31. Dr. Reddy's Laboratories Recent Developments
Table 32. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Information, Head Office, Market Area and Industry Position
Table 33. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Company Profile and Main Business
Table 34. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
Table 35. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
Table 36. Genentech USA, Inc. (F. Hoffmann-La Roche Ltd.) Recent Developments
Table 37. Hetero Drugs Limited Company Information, Head Office, Market Area and Industry Position
Table 38. Hetero Drugs Limited Company Profile and Main Business
Table 39. Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
Table 40. Hetero Drugs Limited Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
Table 41. Hetero Drugs Limited Recent Developments
Table 42. AbbVie Inc. Company Information, Head Office, Market Area and Industry Position
Table 43. AbbVie Inc. Company Profile and Main Business
Table 44. AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
Table 45. AbbVie Inc. Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
Table 46. AbbVie Inc. Recent Developments
Table 47. Teva Pharmaceutical Industries Company Information, Head Office, Market Area and Industry Position
Table 48. Teva Pharmaceutical Industries Company Profile and Main Business
Table 49. Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
Table 50. Teva Pharmaceutical Industries Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
Table 51. Teva Pharmaceutical Industries Recent Developments
Table 52. Novartis AG Company Information, Head Office, Market Area and Industry Position
Table 53. Novartis AG Company Profile and Main Business
Table 54. Novartis AG Immune-mediated Necrotizing Myopathy Treatment Models, Specifications and Application
Table 55. Novartis AG Immune-mediated Necrotizing Myopathy Treatment Revenue and Gross Margin, 2018-2023
Table 56. Novartis AG Recent Developments
List of Figure
Figure 1. Immune-mediated Necrotizing Myopathy Treatment Picture
Figure 2. Global Immune-mediated Necrotizing Myopathy Treatment Industry Market Size and Forecast (US$ million) & (2018-2029)
Figure 3. China Immune-mediated Necrotizing Myopathy Treatment Revenue and Forecast (US$ million) & (2018-2029)
Figure 4. 2018-2029 China Immune-mediated Necrotizing Myopathy Treatment Market Share of Global
Figure 5. Global Immune-mediated Necrotizing Myopathy Treatment Key Participants, Market Share, 2021 VS 2022 VS 2023
Figure 6. Global Immune-mediated Necrotizing Myopathy Treatment Market Share by Company, (Tier 1, Tier 2 and Tier 3), 2018-2023
Figure 7. China Immune-mediated Necrotizing Myopathy Treatment Key Participants, Market Share, 2021 VS 2022 VS 2023
Figure 8. China Immune-mediated Necrotizing Myopathy Treatment Revenue, Domestic VS Import Products, Proportion of China Local Players and Foreign Players, 2018-2023
Figure 9. Immune-mediated Necrotizing Myopathy Treatment Industry Chain
Figure 10. Steroids
Figure 11. Immunosuppressant
Figure 12. Others
Figure 13. By Type, Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029, US$ Million
Figure 14. By Type, Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2029
Figure 15. Hospital
Figure 16. Clinic
Figure 17. Others
Figure 18. By Application, Global Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029, US$ Million
Figure 19. By Application, Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2029
Figure 20. By Region, Global Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2029
Figure 21. North America Immune-mediated Necrotizing Myopathy Treatment Revenue & Forecasts, 2018-2029, US$ Million
Figure 22. By Country, North America Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2023
Figure 23. Europe Immune-mediated Necrotizing Myopathy Treatment Revenue & Forecasts, 2018-2029, US$ Million
Figure 24. By Country, Europe Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2023
Figure 25. Asia Pacific Immune-mediated Necrotizing Myopathy Treatment Revenue & Forecasts, 2018-2029, US$ Million
Figure 26. By Country/Region, Asia Pacific Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2023
Figure 27. South America Immune-mediated Necrotizing Myopathy Treatment Revenue & Forecasts, 2018-2029, US$ Million
Figure 28. By Country, South America Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2018-2023
Figure 29. Middle East & Africa Immune-mediated Necrotizing Myopathy Treatment Revenue & Forecasts, 2018-2029, US$ Million
Figure 30. U.S. Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029, (US$ Million)
Figure 31. By Company, U.S. Immune-mediated Necrotizing Myopathy Treatment Market Share, 2018-2023
Figure 32. By Type, U.S. Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 33. By Application, U.S. Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 34. Europe Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029, (US$ Million)
Figure 35. By Company, Europe Immune-mediated Necrotizing Myopathy Treatment Market Share, 2018-2023
Figure 36. By Type, Europe Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 37. By Application, Europe Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 38. China Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029, (US$ Million)
Figure 39. By Company, China Immune-mediated Necrotizing Myopathy Treatment Market Share, 2018-2023
Figure 40. By Type, China Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 41. By Application, China Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 42. Japan Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029, (US$ Million)
Figure 43. By Company, Japan Immune-mediated Necrotizing Myopathy Treatment Market Share, 2018-2023
Figure 44. By Type, Japan Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 45. By Application, Japan Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 46. South Korea Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029, (US$ Million)
Figure 47. By Company, South Korea Immune-mediated Necrotizing Myopathy Treatment Market Share, 2018-2023
Figure 48. By Type, South Korea Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 49. By Application, South Korea Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 50. Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029, (US$ Million)
Figure 51. By Company, Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Market Share, 2018-2023
Figure 52. By Type, Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 53. By Application, Southeast Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 54. India Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029, (US$ Million)
Figure 55. By Company, India Immune-mediated Necrotizing Myopathy Treatment Market Share, 2018-2023
Figure 56. By Type, India Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 57. By Application, India Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 58. Middle East & Asia Immune-mediated Necrotizing Myopathy Treatment Revenue, 2018-2029, (US$ Million)
Figure 59. By Company, Middle East & Asia Immune-mediated Necrotizing Myopathy Treatment Market Share, 2018-2023
Figure 60. By Type, Middle East & Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 61. By Application, Middle East & Asia Immune-mediated Necrotizing Myopathy Treatment Revenue Market Share, 2022 VS 2029
Figure 62. Research Methodology
Figure 63. Breakdown of Primary Interviews
Figure 64. Bottom-up Approaches
Figure 65. Top-down Approaches
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets